Compare Amgen, Inc. (AMGN) vs Bilibili Inc (BILI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Bilibili Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Bilibili Inc trades at $17.41 (market cap $7.43B). The key difference: Amgen, Inc. is far larger — about 26.4× Bilibili Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Bilibili Inc pays none. Which is the better fit depends on your goals.
| AMGN | BILI | |
|---|---|---|
Market Cap | $196.12B | $7.43B |
Sector | Health | Media |
52-Week High | $388.16 | $35.92 |
52-Week Low | $271.18 | $15.96 |
Enterprise Value | $241.41B | $5.28B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Bilibili (BILI) trades at $17.7, down 0.78% on the day. The stock shows neutral technical signals with mixed moving averages and oscillators. Fundamentally, the company reported Q1 2026 earnings of $0.19 per share, beating estimates, with revenue growth driven by advertising and value-added services. A new $300 million share repurchase program announced in June 2026 signals management confidence.
The outlook is cautiously optimistic, supported by strong analyst buy ratings (83%) and recent earnings beats. Key opportunities include margin expansion and user growth, while risks involve competitive pressures and reliance on the Chinese consumer market. The stock presents a growth opportunity with manageable risks for investors seeking exposure to China's digital content sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Bilibili Inc
Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.
Read more on BILI →
